文献速递脑血管病癫痫

左乙拉西坦与丙戊酸治疗卒中后癫痫发作的有效性:基于目标试验模拟的人群研究

Effectiveness of Levetiracetam vs Valproic Acid for Poststroke Seizure: A Population-Based Study Using a Target Trial Emulation Framework.
PubMed 文献 · Neurology · 2025-11-03

该回顾性队列研究采用目标试验模拟框架,基于台湾全民健康保险研究数据库,纳入2012至2020年首次因癫痫发作住院且出院前新处方左乙拉西坦或丙戊酸单药治疗的卒中后患者。逆概率加权边际结构模型显示,左乙拉西坦组癫痫再住院风险低于丙戊酸组(HR 0.78,95%CI 0.64-0.95),全因死亡率无显著差异。

要点

  • 左乙拉西坦单药治疗与卒中后癫痫发作再住院风险降低相关(HR 0.78)。
  • 左乙拉西坦与丙戊酸在全因死亡率及复合终点上无显著差异。
  • 研究仅针对单药治疗,联合抗癫痫发作药物方案需进一步探索。

核心结论

  • 左乙拉西坦与卒中后癫痫发作患者较低的癫痫再住院风险相关,且全因死亡率与丙戊酸无显著差异。
  • 研究结果为左乙拉西坦作为卒中后癫痫发作的潜在合适治疗选择提供了支持。

研究设计与样本

  • 观察性回顾性队列研究,采用目标试验模拟框架,模拟假想随机试验。
  • 数据来自台湾全民健康保险研究数据库,纳入2012年1月1日至2020年12月31日首次癫痫发作住院且出院前新处方左乙拉西坦或丙戊酸单药治疗的卒中后患者。
  • 最终样本包括740例左乙拉西坦使用者(48.5%)和786例丙戊酸使用者,两组平均年龄均为67.2岁,男性比例相似(左乙拉西坦59.9%;丙戊酸61.3%)。
  • 采用逆概率加权边际结构模型评估结局,调整基线和时变混杂因素。

主要发现

  • 主要结局分析中,左乙拉西坦使用与较低的癫痫再住院风险相关(HR 0.78;95%CI 0.64-0.95)。
  • 次要结局分析中,全因死亡率及癫痫再住院与全因死亡的复合终点均无显著差异。

关键数值与推荐

  • 主要结局为癫痫再住院,左乙拉西坦 vs 丙戊酸的HR为0.78(95%CI 0.64-0.95)。
  • 次要结局包括全因死亡率和癫痫再住院与全因死亡的复合终点,均无显著差异。
  • 证据等级:Class II证据表明左乙拉西坦与较低的癫痫再住院风险相关。

临床怎么用

  • 对于卒中后癫痫发作患者,左乙拉西坦单药治疗可作为优于丙戊酸的选择之一,以降低癫痫再住院风险。
  • 临床决策时需综合考虑患者个体情况,因全因死亡率无显著差异。

局限性

  • 研究为观察性设计,即使采用目标试验模拟框架,仍可能存在未测量混杂。
  • 研究仅聚焦单药治疗,结果不能直接推广至联合抗癫痫发作药物方案。
  • 未来需进一步探索涉及左乙拉西坦的联合抗癫痫发作药物方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Evidence on levetiracetam for poststroke seizures is limited. Understanding whether levetiracetam effectively manages poststroke seizures is important for improving prognosis and preventing further complications in stroke patients. The aim of this study was to assess the risk of seizure rehospitalization between levetiracetam and valproic acid in patients with poststroke seizures. METHODS: Using data from Taiwan's National Health Insurance Research Database, this observational retrospective cohort study followed the target trial emulation framework to emulate a hypothetical randomized trial estimating the effect of levetiracetam for poststroke seizure management. Eligible patients were those who were hospitalized for their first seizure event (index seizure) between January 1, 2012, and December 31, 2020, and were newly prescribed levetiracetam or valproic acid monotherapy before discharge. Patients should have had a stroke-related hospitalization within 2 years before the seizure. Patients prescribed levetiracetam were assigned to the exposure group, whereas those prescribed valproic acid were assigned to the reference group, based on their first prescription after the index seizure. Inverse probability-weighted marginal structural models were used to assess outcomes between levetiracetam and valproic acid, including seizure rehospitalization as the primary outcome. Secondary outcomes included all-cause mortality and a composite of seizure rehospitalization and all-cause mortality. Both baseline and time-varying confounders were adjusted in the models. RESULTS: The final sample included 740 levetiracetam users (48.5%) and 786 valproic acid users, with a mean age of 67.2 years in both groups and a similar proportion of men (59.9% for levetiracetam; 61.3% for valproic acid). In the primary outcome analysis, levetiracetam use was associated with a lower risk of seizure rehospitalization compared with valproic acid (hazard ratio 0.78; 95% CI 0.64-0.95). In secondary outcome analyses, no significant differences were observed in all-cause mortality or the composite of seizure rehospitalization and all-cause mortality. DISCUSSION: Levetiracetam was associated with a lower risk of seizure rehospitalization, with no significant difference in the risk of all-cause mortality. These findings support levetiracetam as a potentially suitable treatment option for patients with poststroke seizures. As this study focused on monotherapy, future investigations should further explore combination antiseizure medication regimens involving levetiracetam. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that levetiracetam is associated with a lower risk of seizure rehospitalization compared with valproic acid in patients with post-stroke seizures.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Huang HY, Wang CC. Effectiveness of Levetiracetam vs Valproic Acid for Poststroke Seizure: A Population-Based Study Using a Target Trial Emulation Framework. Neurology. 2025. PMID: 41183250. doi:10.1212/WNL.0000000000214319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。